Navigation Links
MaxCyte to Present at BIO-Europe Spring 2008 Conference
Date:4/7/2008

GAITHERSBURG, Md., April 7, 2008 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Anthony Recupero, Ph.D., Vice President Business Development at MaxCyte, will present on Tuesday, April 8, 2008, at 2:00PM at the BIO-Europe Spring 2008 Conference in Madrid, Spain. Dr. Recupero's presentation will discuss the development of engineered cell based therapies in the context of clinical experiences in cardiopulmonary diseases and novel approaches to cancer immunotherapy as well as drug delivery.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
4. Prometic to present at the American Chemical Society
5. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
6. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
9. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
11. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
(Date:7/31/2015)... ... , ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin ... has been accepted by AOAC International as Official First Action method. The AOAC ... by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... Corp ., a Madison biotechnology company, has raised $1 million ... the total raised to $3 million in the past two ... verify the efficacy of two products: adhesives that bind tissues ... and medical device coatings that block bacterial adhesion to the ...
... - Sir Ken Robinson has many ... his point about creativity than the story of a little ... a senior advisor to the J. Paul Getty Trust ... creativity and innovation, told the story during a keynote address ...
... 1995, I gave a luncheon speech to the Chicago Bar ... st Century." At that time, many who attended ... that much faith in it. My argument was that the ... maxed out. Municipalities would have to become more creative to ...
Cached Biology Technology:Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 2Sir Ken Robinson: Companies, kids "get" innovation, but K-12 doesn't nurture it 3Creativity, innovation extend to municipalities 2Creativity, innovation extend to municipalities 3Creativity, innovation extend to municipalities 4
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... is speeding up the mortality of trees, and Northern Arizona ... it. Pete Ful, an NAU associate professor in the ... Restoration Institute, is a coauthor of "Widespread Increase of Tree ... be published in the Jan. 23 issue of Science ...
... Significant loss of life, destroyed property and businesses, ... replacing Federal Emergency Management Agency flood maps with ... elevation data, says a new report from the ... accurate flood maps will outweigh the costs, mainly ...
... side, then eating less may help you live longer. ... authors of a new study predict the anti-aging strategy ... even dangerous exercise. "Today there are a lot of ... into this," said Raj Sohal, professor at the University of ...
Cached Biology News:NAU research ties tree mortality trends to climate warming 2More accurate FEMA flood maps could help avoid significant damages and losses 2More accurate FEMA flood maps could help avoid significant damages and losses 3More accurate FEMA flood maps could help avoid significant damages and losses 4Eating less may not extend life 2
... sensitivity of DNA detection has been improved. With ... agarose gel can be detected > 20 ng. ... purified by organic solvent extraction or with other ... well.) DNA excised from agarose gel can ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Rockers, mini, SSM3 & SSM4, Small space saving ... action , Choice of two models: , - ... SSM4 , Digital speed control and built-in ... ,These compact rockers are ideal where gentle mixing ...
... TargeTron(TM) Gene Knockout System provides optimized reagents ... disruption of bacterial genes by insertion of ... retrohoming ability of group II introns and ... the TargeTron group II intron for specific ...
Biology Products: